Health
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., June 02, 2025--ENHERTU plus Pertuzumab Reduced Risk of Disease Progression or Death by 44% vs. THP as 1L Therapy in Patients w/ HER2 positive mBC in DESTINY-Breast09
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/d9026a9ee750c6020b04b7a0a08e8412"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.eMvBHAS8U0TRt.YYawvoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d9026a9ee750c6020b04b7a0a08e8412","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First trial in more than a decade to demonstrate an improvement in outcomes in the first-line setting for a broad population of patients with HER2 positive metastatic breast cancer","length":180,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":303,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer. Results will be presented today during a special late-breaking oral session (LBA #1008) at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting.","length":599,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":229,"tagName":"p"},{"type":"text","content":"In a pre-specified interim analysis, ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% versus THP (hazard ratio [HR]: 0.56; 95% confidence interval [CI]: 0.44-0.71; p<0.00001). Median PFS was 40.7 months (95% CI: 36.5-NC) with ENHERTU plus pertuzumab compared to 26.9 months (95% CI: 21.8-NC) for THP as assessed by blinded independent centr...